[Form 4] EQUIFAX INC Insider Trading Activity

Rhea-AI Filing Summary

Equifax (EFX) CEO and director reported insider transactions on 10/27/2025. The reporting person exercised 27,959 stock options at $191.44 and executed multiple open‑market sales under a Rule 10b5‑1 trading plan adopted on 11/14/2024, plus a G code gift of 47 shares.

Sales included 6,943 shares at a weighted average price of $232.1887 and 6,639 shares at $230.184, among other tranches disclosed. Following the reported transactions, direct beneficial ownership was 142,934 shares. Indirect holdings in grantor retained annuity trusts (GRATs) remained, including 22,045 shares in the “2‑yr Jun 2025 GRAT” and 16,287 shares in the “3‑yr Jul 2024 GRAT.”

Insights

Securities law analyst

Pre‑planned Form 4: option exercise with 10b5‑1 sales.

The insider exercised 27,959 options at $191.44 and reported multiple open‑market sales executed under a Rule 10b5‑1 plan adopted on 11/14/2024. The filing lists granular trade lots with weighted average prices, consistent with routine liquidity and tax management after an option exercise.

After these transactions, direct holdings stood at 142,934 shares, with additional indirect positions across several GRATs. This is administrative disclosure; actual market impact depends on trade size versus average volume and was not addressed in the excerpt.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Begor Mark W

(Last) (First) (Middle)

1550 PEACHTREE STREET, N.W.

(Street)

ATLANTA GA 30309

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EQUIFAX INC [ EFX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/27/2025		M(1)		27,959	A	$191.44	170,940(2)	D
Common Stock	10/27/2025		G		47	D	$0.0000	170,893(2)	D
Common Stock	10/27/2025		S(1)		174	D	$233.8764(3)	170,719(2)	D
Common Stock	10/27/2025		S(1)		204	D	$235.221(4)	170,515(2)	D
Common Stock	10/27/2025		S(1)		3,757	D	$231.4585(5)	166,758(2)	D
Common Stock	10/27/2025		S(1)		4,015	D	$233.0134(6)	162,743(2)	D
Common Stock	10/27/2025		S(1)		6,227	D	$229.2042(7)	156,516(2)	D
Common Stock	10/27/2025		S(1)		6,639	D	$230.184(8)	149,877(2)	D
Common Stock	10/27/2025		S(1)		6,943	D	$232.1887(9)	142,934(2)	D
Common Stock	10/27/2025		S(1)		37	D	$233.9468(10)	43,394	I	2-yr Jun 2025 GRAT
Common Stock	10/27/2025		S(1)		76	D	$234.93	43,318	I	2-yr Jun 2025 GRAT
Common Stock	10/27/2025		S(1)		2,801	D	$233.1237(11)	40,517	I	2-yr Jun 2025 GRAT
Common Stock	10/27/2025		S(1)		3,331	D	$231.5939(12)	37,186	I	2-yr Jun 2025 GRAT
Common Stock	10/27/2025		S(1)		3,995	D	$229.1207(13)	33,191	I	2-yr Jun 2025 GRAT
Common Stock	10/27/2025		S(1)		5,274	D	$232.2704(14)	27,917	I	2-yr Jun 2025 GRAT
Common Stock	10/27/2025		S(1)		5,872	D	$230.1601(15)	22,045	I	2-yr Jun 2025 GRAT
Common Stock								10,500	I	2-yr 2025 GRAT
Common Stock								9,525	I	2-yr Feb 2024 GRAT
Common Stock								11,380	I	2-yr Jul 2024 GRAT
Common Stock								12,333	I	2-yr May 2025 GRAT
Common Stock								16,287	I	3-yr Jul 2024 GRAT

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option/Right to Buy	$191.44	10/27/2025		M			27,959	(16)	02/21/2026	Common Stock	27,959	$0.0000	0.0000	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024.

2. Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

3. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $233.795 to $234.215, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

4. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $234.93 to $235.43, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

5. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $230.74 to $231.734, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

6. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $232.74 to $233.72, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

7. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $228.73 to $229.72, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

8. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $229.74 to $230.72, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

9. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $231.735 to $232.71, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

10. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $233.88 to $234.215, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

11. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $232.85 to $233.80, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

12. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $230.83 to $231.82, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

13. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $228.73 to $229.685, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

14. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $231.845 to $232.81, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

15. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $229.7507 to $230.7266, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.

16. The option vested in three equal annual increments beginning 2/21/2021.

	/s/Lisa Stockard as Attorney-in-Fact	10/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did EFX’s CEO report on Form 4 for 10/27/2025?

An option exercise of 27,959 shares at $191.44, multiple open‑market sales under a Rule 10b5‑1 plan, and a 47-share gift.

Were the sales by EFX’s CEO under a Rule 10b5-1 plan?

Yes. The filing states the trades were effected under a Rule 10b5‑1 plan adopted on 11/14/2024.

What were examples of sale prices disclosed?

Examples include $232.1887 for 6,943 shares and $230.184 for 6,639 shares, reported as weighted averages.

How many EFX shares did the insider hold directly after the transactions?

Direct beneficial ownership was 142,934 shares following the reported transactions.

What indirect EFX holdings remain in GRATs?

Indirect balances include 22,045 shares in the “2‑yr Jun 2025 GRAT” and 16,287 shares in the “3‑yr Jul 2024 GRAT,” among others listed.

When do the exercised options expire and how did they vest?

The option expires on 02/21/2026 and vested in three equal annual increments beginning 02/21/2021.